US antitrust enforcers give Roche approval to buy Spark Therapeutics
December 16, 2019 at 17:38 PM EST
Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics, the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A.
